These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27860501)

  • 1. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.
    McCarthy M
    BMJ; 2015 Dec; 351():h6702. PubMed ID: 26656272
    [No Abstract]   [Full Text] [Related]  

  • 3. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [GLP-1 receptor agonists: current state].
    Larger É; Dehghani L; Saatdjian L; Wucher H
    Rev Prat; 2015 Oct; 65(8):1037-8. PubMed ID: 26749700
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
    Geurin MD
    Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
    Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
    Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
    [No Abstract]   [Full Text] [Related]  

  • 8. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonist confer target organ protection in type 2 diabetes.
    Bonnet F
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S1-2S2. PubMed ID: 28431665
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of GLP-1 receptor agonists and their fixed combination with insulin in the treatment of type 2 diabetes mellitus].
    Schroner Z; Uličiansky V
    Vnitr Lek; 2019; 65(4):284-288. PubMed ID: 31091948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes.
    Montori VM; Rodriguez-Gutierrez R
    Ann Intern Med; 2016 Jan; 164(2):127-8. PubMed ID: 26641027
    [No Abstract]   [Full Text] [Related]  

  • 16. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modern antihyperglycaemic agents--what is the patient benefit?].
    Siegmund T
    MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585
    [No Abstract]   [Full Text] [Related]  

  • 19. An overview of new GLP-1 receptor agonists for type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.